DEVELOP NOVEL AND INNOVATIVE SMALL MOLECULE THERAPEUTICS TO TREAT (POST-EXPOSURE THERAPEUTIC) INFECTIONS BY BOTH FILOVIRUS FAMILY MEMBERS (EBOLA VIRUSES AND MARBURG VIRUSES)
$2,594,320
| Recipient | MICROBIOTIX, INC. UEI SCNKBDM341T1 |
|---|---|
| Award ID | HDTRA118C0001 |
| Award amount | $2,594,320 |
| Award type | DEFINITIVE CONTRACT |
| Awarding agency | Department of Defense — Defense Threat Reduction Agency |
| NAICS | 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) |
| PSC | AD92 |
| Start date | Dec 15, 2017 |
| End date | Mar 14, 2022 |
| Place of performance | WORCESTER, MA |
| Record updated | Nov 9, 2021 |
View the official award record
More awards won by MICROBIOTIX, INC.
TO DEVELOP THE PPZ SERIES OF SMALL MOLECULE PAN-FILOVIRUS ENTRY INHIBITORS THROUGH LEAD OPTIMIZATION, SELECTION OF A PRECLINICAL CANDIDATE, AND IND-ENABLING PRECLINICAL STUDIES.
Department of Health and Human Services · $8,795,790 · Nov 1, 2022
TO DEVELOP PHENOXYACETAMIDE T3SS INHIBITORS AS ADJUNCTIVE AGENTS TO ANTIBACTERIAL THERAPY FOR MDR P. AERUGINOSA INFECTIONS.
Department of Health and Human Services · $7,263,391 · Jul 1, 2020
Our catalog shows awards of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
Awards tell you who won. Bids tell you what's next. BidCatch scans 100+ federal, state, and local sources every night and sends the new opportunities matching your trade — before they're awarded to someone else. Free for 14 days, then $49.99/month.
Search open bids